Second Sight Announces First Successful Implant of Model of Orion I Visual Cortical Prosthesis

SYLMAR, Calif., April 8, 2015 -- Second Sight Medical Products, Inc. (EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to restore functional vision to blind patients, today announced the first successful implant of a mechanical model of the Orion(TM) I Visual Cortical Prosthesis ("Orion I") in an animal study.

The first implant was performed as part of a phase I pre-clinical study, which is designed to evaluate fit, form, stability and biocompatibility. This study, which is expected to run through the end of the year, is the first major milestone in the Company's development of the Orion I. Fully functional prototypes are expected to be completed later this year with active animal implants scheduled to begin by Q1 2016; the first human clinical trials are planned to commence by Q1 2017. Assuming positive initial results in patients and discussions with regulators, an expanded pivotal clinical trial for global market approvals is planned.

SAPIEN 3 Valve Demonstrates Low Mortality, Excellent 30-Day Outcomes In High- And Intermediate-Risk Patients

SAN DIEGO, March 15, 2015 -- Edwards Lifesciences Corporation (EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that 30-day outcomes for high- and intermediate-risk patients treated with the SAPIEN 3 transcatheter aortic valve demonstrated the lowest all-cause mortality rates of any of the PARTNER studies, as well as excellent clinical outcomes on the other components of the primary endpoint measures of stroke and paravalvular regurgitation.  This first report of SAPIEN 3 data in the United States, and first report on intermediate risk transcatheter aortic valve replacement (TAVR) patients, was presented as part of the late-breaking clinical trials at the American College of Cardiology's (ACC) 64^th Annual Scientific Session in San Diego.

Bacterin Announces Distribution Agreement With Spartan Medical for DOD and VA Medical Centers

BELGRADE, Mont., March 10, 2015 -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of bone graft material, today announced it has signed a national distribution agreement with Spartan Medical, Inc., a service-disabled, veteran-owned, small business focused on distribution to government medical facilities.

Under the agreement, Spartan Medical will distribute Bacterin's proprietary product portfolio to the medical centers affiliated with the US Department of Defense (DOD) and the US Department of Veteran's Affairs (VA). Spartan Medical is an established distribution entity that provides best-in-class products and services to its customers, with specific experience in orthopedic and biologics distribution, and government contracting.

TSO3 enters into first commercial agreement for STERIZONE® VP4 Sterilizer

QUÉBEC, March 6, 2015 - TSO₃ Inc. (TOS.TO) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has signed its first commercial agreement with Getinge Infection Control in support of the launch of the STERIZONE^® VP4 Sterilization System. The non-exclusive agreement covers multiple markets in which Getinge has significant market share, including North America and other selected markets. Efforts to launch the product will begin immediately.